Drug Report History #8941
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that have changed between versions will be highlighted in yellow, and the changes will be clearly marked as updated.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow, and the change will be clearly marked as updated.
| Field | Version v12-EN | Version v5-FR |
|---|---|---|
| Language | English (Updated) | French |
| Date Updated | 2018-10-17 (Updated) | 2018-04-18 |
| Drug Identification Number | 00397466 | 00397466 |
| Brand name | CYSTO-CONRAY II | CYSTO-CONRAY II |
| Common or Proper name | Iothalamate Meglumine Injection USP 17.2% | Iothalamate Meglumine Injection USP 17.2% |
| Company Name | LIEBEL-FLARSHEIM CANADA INC | LIEBEL-FLARSHEIM CANADA INC |
| Ingredients | IOTHALAMATE MEGLUMINE | IOTHALAMATE MEGLUMINE |
| Strength(s) | 172MG | 172MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | URETHRAL | URETHRAL |
| Packaging size | 250 mL, 500 mL | 250 mL, 500 mL |
| ATC code | V08AA | V08AA |
| ATC description | X-RAY CONTRAST MEDIA, IODINATED | X-RAY CONTRAST MEDIA, IODINATED |
| Reason for shortage | Shortage of an active ingredient. | Shortage of an active ingredient. |
| Anticipated start date | ||
| Actual start date | 2017-05-03 | 2017-05-03 |
| Estimated end date | 2018-10-22 (Updated) | 2018-08-20 |
| Actual end date | ||
| Shortage status | Actual shortage | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | Shipment is in transit. For more information, please contact Methapharm Inc. at 1-800-287-7686, [email protected], or by fax at 1-519-751-9149. (Updated) | For more information, please contact Methapharm Inc. at 1-800-287-7686, [email protected], or by fax at 1-519-751-9149. |
| Health Canada comments |